ProMIS Neurosciences Files 8-K Report

Ticker: PMN · Form: 8-K · Filed: 2024-04-30T00:00:00.000Z

Sentiment: neutral

Topics: 8-k, financial-statements, regulation-fd

TL;DR

ProMIS Neurosciences filed an 8-K on 4/30/24 for financial statements and other events.

AI Summary

On April 30, 2024, ProMIS Neurosciences Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD disclosure and other events. No specific new material events or financial figures beyond standard reporting requirements were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates standard corporate reporting, including financial statements and exhibits, which are crucial for investors to stay informed about the company's financial health and operational status.

Risk Assessment

Risk Level: low — The filing appears to be routine and does not disclose any immediate significant risks or material changes.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by ProMIS Neurosciences Inc.?

The primary purpose of this 8-K filing is to report financial statements and exhibits, along with a Regulation FD disclosure and other events, as of April 30, 2024.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is April 30, 2024.

What is the principal executive office address for ProMIS Neurosciences Inc.?

The principal executive offices are located at Suite 200, 1920 Yonge Street, Toronto, Ontario, M4S 3E2.

What is the telephone number for ProMIS Neurosciences Inc.?

The registrant's telephone number, including area code, is (416) 847-6898.

What was the former name of ProMIS Neurosciences Inc.?

The former name of ProMIS Neurosciences Inc. was AMORFIX LIFE SCIENCES LTD, with a date of name change on August 31, 2006.

Filing Stats: 1,254 words · 5 min read · ~4 pages · Grade level 16.4 · Accepted 2024-04-30 07:56:02

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On April 30, 2024, ProMIS Neurosciences Inc. (the "Company") issued a press release announcing the publication of a paper titled, "Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies," in the online journal, bioRxiv (the "Press Release"). A copy of the Press Release is attached hereto as Exhibit 99.1. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On April 30, 2024, the Company issued the Press Release referenced above. The study characterized and compared the binding profile of various amyloid-beta (A)-directed antibodies to monomers, soluble oligomers and insoluble A fibrils. The results indicate that selectivity for soluble toxic A oligomers may be a driver of clinical efficacy and indicated that PMN310 displayed the greatest degree of oligomer selectivity. PMN310, the Company's novel monoclonal antibody being evaluated as a treatment for Alzheimer's disease ("AD"), is currently undergoing Phase 1a clinical studies in healthy volunteers, with initial safety and pharmacokinetic data expected in mid-2024. A-directed antibodies tested clinically for therapeutic activity against AD have shown varying degrees of efficacy. A side-by-side comparison of antibody binding to different molecular species of A conducted by ProMIS provided insight into the observed variability in clinical outcomes. A correlation was observed between reported clinical efficacy and the ability of an antibody to retain binding to soluble oligomers from AD brains when faced with monomer competition. PMN310 showed a high degree of resistance to monomer competition. Importantly, unlike all other antibodies tested, PMN310 also avoided binding to plaque and vascular deposits of Ab. Consequently, PMN310, may reduce the risk of brain edema (ARIA-E) and microhemorrhages (ARIA-H) often associated with plaque-binding antibodies. This premise is supported by the results showing that weekly dosing of a murine version of PMN310 at very high doses (800 mg/kg) for 26 weeks in a mouse model of AD did not cause any detectable brain hemorrhages upon microscopic examination.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this Current Report on Form 8-K constitutes forward-looking statements and forward-looking information (collectively, "forward-looking information") within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "excited to", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Specifically, this Current Report on Form 8-K contains forward-looking information relating to the study and reported therapeutic activity and preferential targeting of toxic soluble aggregates by A-directed antibodies and the potential implications thereof, the Company's expectations regarding its clinical development of its lead product, PMN310, for AD, and the Company's anticipated top-line data readout for our Phase 1a study in the first half of 2024 and plans to advance into a Phase 1b multiple ascending dose study in AD patients. Statements containing forward-looking information are not historical facts but instead represent management's current expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking informa

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated April 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROMIS NEUROSCIENCES INC. Date: April 30, 2024 By: /s/ Neil Warma Name: Neil Warma Title: Chief Executive Officer

View on Read The Filing